VIRACTA THERAPEUTICS INC

$2.15 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About VIRACTA THERAPEUTICS INC

Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.

Stock Analysis

last close $2.15
1-mo return -17%
3-mo return -24.6%
avg daily vol. 176T
52-week high 13.08
52-week low 1.82
market cap. $79M
forward pe -
annual div. -
roe -46.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 46.7%
baraka

Subscribe now for daily local and international financial news

Subscribe